BioCentury
ARTICLE | Company News

Ex Scientia, Sanofi to design diabetes bispecifics

May 9, 2017 4:14 PM UTC

Artificial intelligence company Ex Scientia Ltd. (Dundee, U.K.) said it partnered with Sanofi (Euronext:SAN; NYSE:SNY) to design and develop bispecific antibodies to treat metabolic diseases. Ex Scientia declined to disclose specific indications or targets covered by the partnership.

The biotech said it will use its platform to evaluate combinations of drug targets in diabetes that work synergistically, and prioritize target pairs with bispecific binding potential. Ex Scientia was spun out of the University of Dundee to commercialize its computational algorithm that mines medicinal chemistry literature to predict new ligands that bind specific combinations of G protein-coupled receptors (see BioCentury, Jan. 24, 2013)...

BCIQ Company Profiles

Exscientia plc

Sanofi